Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva, Adina Vultur, John T Lee, Rajasekharan Somasundaram, Mizuho Fukunaga-Kalabis, Angela K Cipolla, Bradley Wubbenhorst, Xiaowei Xu, Phyllis A Gimotty, Damien Kee, Ademi E Santiago-Walker, Richard Letrero, Kurt D'Andrea, Anitha Pushparajan, James E Hayden, Kimberly Dahlman Brown, Sylvie Laquerre, Grant A McArthur, Jeffrey A Sosman, Katherine L Nathanson Show all
Cancer Cell | CELL PRESS | Published : 2010
Awarded by National Cancer Institute
Awarded by NATIONAL CANCER INSTITUTE
We thank T. Nguyen and F. Keeney for assistance with graphics, T. Wang for help with Annexin-V analysis, and J. Kong, Y, Chen, S. Huang, M. Neri, and S. Lee for technical assistance. We thank the Microscopy and Flow Cytometry facilities at the Wistar Institute and G. Bollag for providing PLX4720. We apologize to those whose work is not mentioned here due to space constraints. This work was supported by grants from the National Cancer Institute (P01 CA114046, P01 CA025874, P30 CA010815, RO1 CA117881), the Adelson Medical Research Foundation, and GlaxoSmithKline. Sylvie Laquerre is an employee and shareholder of GlaxoSmithKline.